All studies
Critical care · Claims · US

Garry 2022

COVID-19

ITT, ATSuperiorityIndustry, Government0/5 disclosures
Comparisons
2
In the analysis
2
all comparisons pooled
Target trials
1
Emulations reported
1
2 treatments

Comparisons

2 shown
Randomized trialEmulation
Outcome & target trialTrial vs emulationOn a shared scaleAgreement
28-day mortality
vs RECOVERY·HR·Efficacy
0.640.51–0.81
1.020.89–1.18
no overlap3.37 SE apart
28-day mortality
vs RECOVERY·HR·Efficacy
0.820.72–0.94
1.321.21–1.45
no overlap5.79 SE apart

Design and methods

Estimand
ITT, AT
Design hypothesis
Superiority
Matching / weighting
1:1 PS matching, IPTW
Analysis method
Cox PH
Missing data
NR
Covariates adjusted
6
DAG
No
QBA
No

Data and sample

Data type
Claims
Data sources
1
Geography
US
Treated
8812
Control
8812
Emulations
1
Treatments compared
2

Transparency

0/5
Protocol
No pre-registration
Preprint
No preprint
Data availability
Unavailable
Code availability
Unavailable
Conflicts of interest
Not declared
Funding
Not declared

The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.

Provenance

Review key
2022_Gary_COVID_ConferenceAbstract
DOI
https://dx.doi.org/10.1002/pds.5518
Affiliations
Aetion Inc, US Food and Drug Administration, HealthVerity
Sector
Industry, Government
Target trials (study level)
RECOVERY
Registration
NCT04381936